Compare Cytokinetics Inc (CYTK) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Jabil Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Jabil Inc trades at $303.5 (market cap $31.38B). The key difference: Jabil Inc is far larger — about 3.7× Cytokinetics Inc's market cap, and Jabil Inc pays a 0.11% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Jabil Inc for 23 Days on average.
| CYTK | JBL | |
|---|---|---|
Market Cap | $8.50B | $31.38B |
Volume | 2,395,556 | 1,418,629 |
Sector | Health | Technology |
52-Week High | $87.26 | $385.50 |
52-Week Low | $54.76 | $192.49 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $8.60B | $33.66B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
JBL trades at $299.47, down 3.14% today amid a bearish technical signal, though recent Q4 2026 earnings beat expectations with EPS of $4.40 versus $4.07 expected. The company shows strong fundamentals with revenue growth to $29.80B in 2025 and projected 24% growth in fiscal 2027 driven by AI infrastructure demand. Analyst consensus remains bullish with a $434.75 price target, representing 45% upside potential from current levels.
The stock presents a compelling growth opportunity with robust AI-driven expansion and strong institutional support, though technical weakness and market volatility pose near-term risks. With zero sell ratings and 61% buy recommendations, Wall Street sees significant upside despite recent price pressure from broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
